Терапевтический ангиогенез в лечении больных ишемической болезнью сердца. Взгляд клинициста

Download

References

References

1. Бокерия Л. А., Голухова Е. З., Еремеева М. В. и др. Первый опыт клинического применения терапевтического ангиогенеза с использованием гена VEGF165 человека // Бюлл. НЦССХ им. А. Н. Бакулева РАМН. - 2004. - Т. 5, № 4. - С. 134-142.
2. Вахромеева М. Н. Отбор больных и оценка результатов трансмиокардиальной лазерной реваскуляризации с помощью методов ядерной медицины: Дис. … д-ра биол. наук. - М., 2003.
3. Демидова О. А. Комбинированное лечение хронической ишемии нижних конечностей с использованием ангиогенеза: Дис. … канд. мед. наук. - М., 2005.
4. Лукашкин М. А. Экспериментальное обоснование и оценка первого опыта применения клинического ангиогенеза с использованием генов VEGF и bFGF: Дис. … канд. мед. наук. - М., 2005.
5. Baffour R., Berman J., Garb J. L. et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose-response effect of basic fibroblast growth factor // J. Vasc. Surg. - 1992. - Vol. 16. - P. 181-191.
6. Banai S., Jaklitsch M. T., Shou M. et al. Angiogenicinduced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs // Circulation. - 1994. - Vol. 89. - P. 2183-2189.
7. Banai S., Shweiki D., Pinson A. et al. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis // Cardiovasc. Res. - 1994. - Vol. 28. - P. 1176-1179.
8. Bauters C., Asahara T., Zheng L. P. et al. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb // Amer. J. Physiol. - 1994. - Vol. 267. - P. H1263-H1271.
9. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis // Nat. Med. - 2000. - Vol. 6. - P. 389-395.
10. Carmeliet P., Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin // Ann. N. Y. Acad. Sci. - 2000. - Vol. 902. - P. 249-262; discus. 262-264.
11. Carmeliet P., Ferreira V., Breier G. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele // Nature. - 1996. - Vol. 380. - P. 435-439.
12. Celletti F. L., Waugh J. M., Amabile P. G. et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression // Nat. Med. - 2001. - Vol. 7. - P. 425-429.
13. Ferrara N., Carver-Moore K., Chen H. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene // Nature. - 1996. - Vol. 380. - P. 439-442.
14. Folkman J., Klagsbrun M. Angiogenic factors // Science. - 1987. - Vol. 235. -P. 442-447.
15. Gao Y., Lecker S., Post M. J. et al. Inhibition of ubiquitin- proteasome pathway-mediated IkappaBalpha degradation by a naturally occurring antibacterial peptide // J. Clin. Invest. - 2000. - Vol. 106. - P. 439-448.
16. Gille J., Khalik M., Konig V., Kaufmann R. Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes // J. Invest. Dermato. - 1998. - Vol. III. - P. 1160-1165.
17. Grines C. L., Watkins M. W., Helmer G. et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris // Circulation. - 2002. - Vol. 105. - P. 1291-1297.
18. Hamaway A., Lee L., Crystal R. et al. Cardiac angiogenesis and gene therapy: a strategy for myocardial revascularization // Curr. Opin. Cardiol. - 1999. - Vol. 14. - P. 515-522.
19. Hammond H. K., McKiman M. D. Angiogenic gene therapy for heart disease: A review of animal studies and clinical trials // Cardiovasc. Res. - 2001. - Vol. 49. - P. 561-567.
20. Harada K., Grossman W., Friedman M. et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts // J. Din. Invest. - 1994. - Vol. 94. - P. 623-630
21. Hedman M. et al. Safety and feasibility of catheterbased local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and instent restenosis and in the traetment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT) // Circulation. - 2003. - Vol. 107. - P. 2677-2683.
22. Hellstrom M., Gerhardt H., Kalen M. et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis // J. Cell. Biol. - 2001. - Vol. 153. - P. 543-553.
23. Henry T., Annex B., Azrin M. et al. Final results of the VIVA trial of rhVEGF human therapeutic angiogenesis // Circulation. - 1999. - Vol. 100. - P. 1-476.
24. Isner J. Angiogenesis for revascularization of ischemic tissues // Eur. Heart J. - 1997. - Vol. 18. - P. 1-2.
25. Kornowski R., Fuchs S., Leon M. B., Epstein S. E. Delivery strategies to achieve therapeutic myocardial angiogenesis // Circulation. - 2000. -Vol. 101.- P. 454-458.
26. Laham R. J., Chronos N. A., Pike M. et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a Phase I open-label dose escalation study // J. Amer. Coll. Cardiol. - 2000. - Vol. 36. - P. 2132-2139.
27. Laham R. J., Rezaee M., Post M. et al. Intracoronary and intravenous administration of basic fibroblast growth factor: Myocardial and tissue distribution // Drug. Metab. Dispos. - 1999. - Vol. 27. - P. 821-826.
28. Laham R. J., Sellke F. W., Edelman E. R. et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial // Circulation. - 1999. - Vol. 100. - P. 1865-1871.
29. Laham R. J., Simons M., Peariman J. D. et al. Magnetic resonance imaging demonstrates improved regional systolic wall motion and thickening and myocardial perfusion of myocardial territories treated by laser myocardial revascularization // J. Amer. Coll. Cardiol. - 2002. - Vol. 39. - P. 1-8.
30. Lederman R. et al. Therapeutic angiogenesis with recombinant fibroblast growth 2 for intermittent claudication (the TRAFFIC study): a randomized trial // Lancet. - 2002. - Vol. 359. - P. 2053-2058.
31. Li J., Post M., Volk R. et al. PR39, a peptide regulator of angiogenesis // Nat. Med. - 2000. - Vol. 6. - P. 49-55.
32. Losordo D., Vale P., Hendel R. et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patrients with chronic myocardial ischemia // Circulation. - 2002. - Vol. 105. - P. 2012-2018.
33. Losordo D., Vale P., Isner J. Gene therapy for myocardial angiogenesis // Amer. Heart J. - 1999. - Vol. 138. - P. S132-141.
34. Parsons-Wingerter P., Elliott K. E., Dark J. I., Farr A. G. Fibroblast growth factor-2 selectively stimulates angiogenesis of small vessels in arterial tree // Arterioscler. Thromb. Vasc. Biol. - 2000. - Vol. 20. - P. 1250-1256.
35. Pearlman J. D., Hibberd M. G., Chuang M. L. et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis // Nat. Med. - 1995. - Vol. 1. - P. 1085-1089.
36. Pecher P., Schumacher B. Angiogenesis in ischemic human myocardium: clinical results after 3 years // Ann. Thorac. Surg. - 2000. - Vol. 69. - P. 1414-1419.
37. Post M. J., Laham R., Selike F. W., Simons M. Therapeutic angiogenesis in cardiology using protein formulations // Cardiovasc. Res. - 2001. - Vol. 49. -P. 522-531.
38. Pu L. Q., Sniderman A. D., Arekat Z. et al. Angiogenic growth factor and revascularization of the ischemic limb: Evaluation in a rabbit model // J. Surg. Res. - 1993. - Vol. 54. - P. 575-583.
39. Pu L. Q., Sniderman A. D., Brassard R. et al. Enhanced revascularization of the ischemic limb by angiogenic therapy // Circulation. - 1993. - Vol. 88. - P. 208-215.
40. Rosengart T., Lee L., Patel S. et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease // Ibid. - 1999. - Vol. 100. - P. 468-474.
41. Rosengart T., Patel S., Crystal R. Therapeutic angiogenesis: protein and gene therapy delivery strategies // J. Cardiovasc. Risk. - 1999. - Vol. 6. - P. 29-40.
42. Ruel M., Laham R., Parker J. et al. Long-term effects of surgical angiogenic therapy with FGF-2 protein // J. Thorac. Cardiovasc. Surg. - 2002. - Vol. 124. - P. 28-34.
43. Safi J. Jr., Gloe T., Riccioni T. et al. Gene therapy with angiogenic factors: a new potential approach to the treatment of ischemic disease // J. Mol. Cell. Cardiol. - 1997. - Vol. 29. - P. 2311-2325.
44. Schaper W., Ito W. Molecular mechanisms of collateral vessel growth // Circ. Res. - 1996. - Vol. 79. - P. 911-919.
45. Schultz A. et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation // Circulation. - 1999. - Vol. 100. - P. 547-552.
46. Schumacher B., Pecher P., von Specht B. et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease // Ibid. - 1998. - Vol. 97. - P. 645-650.
47. Sellke F., Laham R., Edelman E. et al. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results // Ann. Thorac. Surg. - 1998. - Vol. 65. - P. 1540-1544
48. Sellke F. W., Ruel M. Vascular growth factors and angiogenesis in cardiac surgery // Ibid. - 2003. - Vol. 75. - P. S685-690.
49. Sellke F., Simons M. Angiogenesis in cardiovascular disease: current status and therapeutic potential // Drugs. - 1999. - Vol. 58, № 3. - P. 391-396.
50. Semenza G. L. Hypoxia-inducible factor 1: Master regulator of 02 homeostasis // Curr. Opin. Genet. Dev. - 1998. - Vol. 8. - P. 588-594.
51. Semenza G. L. HIF-1 and human disease: One highly involved factor // Genes Dev. - 2000. - Vol. 14. - P. 1983-1991.
52. Semenza G. L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia // J. Appl. Physiol. - 2000. - Vol. 88. - P. 1474-1480.
53. Simons M. Angiogenesis therapies for coronary artery disease. Ch. 20 // Cardiac. Drug. Development. Guide / Ed. M. K. Pugsley. - Totowa, NJ.: Humana Press Inc., 2002.
54. Simons M., Ware A. Therapeutic angiogenesis in cardiovascular disease // Nature Reviews/Drug. Discovery. - 2003. - Vol. 2. - P. 863-871.
55. Simons M. Therapeutic coronary angiogenesis: A fronte praecipitium a tergo lupi? // Amer. J. Physiol. - 2001. - Vol. 280. - P. H1923-H1927.
56. Simons M., Annex B. H., Laham R. J. et al. Pharmacological treatment of coronar artery disease with recombinant fibroblast growth factor-2: Doubleblind, randomized, controlled clinical trial // Circulation. - 2002. - Vol. 105. - P. 788-793.
57. Simons M., Laham R. J., Post M. J., Selike F. W. Therapeutic angiogenesis: Potential role of basic FGP in patients with severe ischemic heart disease // BioDrugs. - 2000. - Vol. 14. - P. 13-20.
58. Symes J., Losordo D., Vale P. et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease // Ann. Thorac. Surg. - 1999. - Vol. 68. - P. 830-836, discus. 836-837.
59. Takeshita S., Pu L. Q., Stein L. A. et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia // Circulation. - 1994. - Vol. 90. - P. II228-II234
60. Unger E. P., Banai S., Shou M. et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model // Amer. J. Physiol. - 1994. - Vol. 266. - P. H1588-H1595.
61. Vale P., Losordo D., Milliken C. et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia // Circulation. - 2001. - Vol. 103. - P. 2138-2143.
62. Ware J. A., Simons M. Angiogenesis in ischemic heart disease // Nat. Med. - 1997. - Vol. 3. - P. 158-164.
63. Yee A., Rosengart T. Angiogenesis and gene therapy for the treatment of coronary artery disease. Ch. 16 // Advanced therapy in cardiac surgary. 2-nd ed. / Eds K. L. Franco, E. D. Verrier. - London: B C Deaker Inc, 2003.
64. Yla-Herttuala S., Martin J. F. Cardiovascular gene therapy // Lancet. - 2000. - Vol. 355. - P. 213-222.

News

Chief Editor

Elena Z. Golukhova, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery

Sort by

Если вы заметили опечатку, выделите текст и нажмите alt+A